Irvine, Calif. (PRWEB) August 22, 2016
Proove Biosciences, Inc., a top healthcare research and development company, is proud to announce its nomination for the Orange County Business Journal (OCBJ) 2016 Innovator of the Year Award, which honors, recognizes and celebrates individuals and organizations that are creating game-changing products and services.
The announcement comes shortly after being named a finalist in the Orange County Technology Alliance’s 2016 High-Tech Innovation Awards and joining the Inc. 5000 list of America’s fastest-growing private companies. Brian Meshkin, founder and CEO of Proove Biosciences, is excited to receive this latest acknowledgement from a prominent local publication: “Our mission has always been to analyze the big data of clinical and genetic information to provide physicians and patients with information to improve decisions about diagnosis and treatment. By receiving a nomination from OCBJ for our innovation in healthcare, our entire team feels a sense of gratification.”
Founded in 2009, Proove Biosciences — the Healthcare Decision Company™ — is considered to be a commercial and educational leader in the research, investigation and development of patent-protected tests that combine genetic and clinical data into reports that help physicians individualize — and optimize — medicine selection and dosing. As an innovator, Proove continues to leverage its products to address the national prescription opioid abuse epidemic, which claims thousands of lives each year. Through the Proove Opioid Risk test and the Proove Pain Perception Profile, for example, physicians across the country are able to better treat more than 100,000 patients by assessing risk for abusing opioids, objectively assessing their pain perception, and evaluating which medication options each patient is likely to respond to most favorably.
“As the opioid epidemic continues to plague our society, we could not be more dedicated to reducing abuse and overdose through helping physicians identify which patients are safe to take opioids and which patients must avoid them,” adds Meshkin, a 20-year industry veteran whose accolades include being a finalist for the 2015 and 2016 Ernst & Young Entrepreneur of the Year Award and winner of the 2016 Orange County Business Journal Excellence in Entrepreneurship Award. “Through decreasing the risk of treatment failure, lowering costs to insurers, and relieving society of the emotional and financial burdens associated with addiction and other avoidable consequences, our incredible team of researchers, clinicians, biostatisticians, software engineers, laboratory scientists, and other contributors are proud to be making a real difference in the local community and on a national level.”
Only in its second year, the OCBJ Innovator of the Year Awards is preparing for its upcoming ceremony and luncheon on September 22, 2016 at the Hotel Irvine, where Proove will be attending alongside more than 70 trailblazers from industries of all types. To purchase tickets, please visit: http://www.ocbj.com.
To learn more about Proove Biosciences, visit http://www.proove.com. With media inquiries, please contact Leslie Licano at leslie(at)beyondfifteen(dot)com or (949)-733-8679.
About Proove Biosciences
Proove Biosciences -- the Healthcare Decision Company™ -- is the commercial and educational leader in the research, investigation and development of patent-protected tests that combine genetic and clinical data into reports to help physicians to individualize -- and optimize -- medicine selection and dosing. Supported by leading medical experts and institutions across the globe, the reports facilitate objective decision-making to improve outcomes for patients, providers and insurers. Backed by science and driven by data, Proove is revolutionizing individualized medicine. With a patented bioinformatics platform that delivers therapy-defining information that allows prescribers to evaluate pain tolerance, identify risk for dependence and addiction, predict response and immunity to opioid and non-opioid pain medication, and assess patient drug metabolism, Proove provides the most technologically advanced solutions to enable accurate and evidence-based medical decision-making rather than "trial-and-error" approaches. Proove helps reduce the risk of treatment failure, decrease costs to insurers and relieve society of the emotional and financial burdens associated with addiction and other avoidable consequences. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).